In this study, 18 genes showing a high frequency of mutation in MDS were adopted for sequencing analysis, including the epigenetic modifiers ASXL1, DNMT3A, EZH2, TET2, IDH1/2 and BCOR; the RNA spliceosome genes SF3B1, SRSF2, U2AF1, and ZRSR2; the transcription factors CEBPA, GATA2, RUNX1, and SETBP1; the adhesion molecule STAG2; and the tumor suppressors WT1 and TP53. This evidence concerns the gene CEBPA and myelodysplastic syndrome.